Procainamide-induced lupus erythematosus. Clinical and laboratory observations.
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D000917:Antibody Formation; D001327:Autoimmune Diseases; D002417:Cattle; D003168:Complement Fixation Tests; D004247:DNA; D005260:Female; D006657:Histones; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009690:Nucleic Acid Conformation; D009691:Nucleic Acid Denaturation; D009698:Nucleoproteins; D010998:Pleurisy / Q000150:complications; D011233:Precipitin Tests; D011241:Prednisone / Q000627:therapeutic use; D011342:Procainamide / Q000009:adverse effects*; D011817:Rabbits; D012217:Rheumatoid Factor / Q000032:analysis; D014316:Tritium
D000974:Antibodies, Antinuclear; D006657:Histones; D009698:Nucleoproteins; D014316:Tritium; D004247:DNA; D012217:Rheumatoid Factor; D011342:Procainamide; D011241:Prednisone